Clinical trial
clinical trial
ASSURE: adjuvant sorafenib or sunitinib for ufavorable renal carcinoma
Intervention
Drug intervention
Intervention Type
drug intervention
has_intervention
Nexavar
drug intervention
Nexavar
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Adjuvant therapy
drug intervention
Adjuvant therapy
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Sutent
drug intervention
Sutent
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Sorafenib
drug intervention
Sorafenib
Intervention
intervention
planned process
planned process
process
occurrent
entity
Drug intervention
drug intervention
Sunitinib
drug intervention
Sunitinib
Intervention
intervention
planned process
planned process
process
occurrent
entity
Contact
has contact
has_contact
Berenberg, Jeffrey
PI
has PI
has_PI
Topic
has topic
has_topic
kidney cancer
Funded by
funded by
funded_by
Cancer Trials Support Unit
Phase
Phase 3 clinical trial
has phase
has_phase
Phase 3
Performed by
human study performed by
human_study_performed_by
Clinical Protocol & Data Management Shared Resource
http://www.clinicaltrials.gov/ct2/show/NCT00326898?term=ECOG-E2805&rank=1
ClinicalTrials.gov url
ClinicalTrials.gov url
CTurl
http://www.cancer.gov/clinicaltrials/featured/trials/ecog-e2805
Website(s)
has URL
has_url
http://www.cancer.gov/clinicaltrials/search/view?cdrid=478976&version=healthprofessional
Surgery is the primary treatment for most cases of kidney cancer. While surgery alone often cures patients with early stage disease, individuals with more advanced disease have an increased risk of cancer recurrence after surgery.
In this trial, patients who have tumors that can be surgically removed and who are at high risk for recurrence are given sunitinib (Sutent®), sorafenib (Nexavar®), or a placebo as postoperative (adjuvant) therapy. Patients given the placebo will be receiving the current standard of care for their condition, which is no adjuvant therapy.
Sunitinib and sorafenib are targeted therapies that block cell proliferation and the growth of new blood vessels to tumors (a process called angiogenesis). Angiogenesis is important for the growth and spread of malignant kidney tumors and blocking it may help prevent the growth of cancer cells that remain after surgery.
Resource Description
resource_description
Males and females age 18 and older with histologically or cytologically confirmed renal cell carcinoma, including clear cell carcinoma and nonclear cell carcinoma; no collecting duct or medullary carcinomas.
Study Population
study population
has_study_population
2011-06-29T17:13:15.875-05:00
awendicke (Annemarie Wendicke)
2011-09-23T10:52:18.520-05:00
workflow state
Published
mwilson (Melanie Wilson)
nvasilevsky
Interventional study
Research project
research project
Human Study
human study
human study
planned process
planned process
Quantitative human study
process
occurrent
entity